Cytosolix, Inc.

Colin has over thirty years of experience as a public and private life science company Chairman, Executive Chairman, Board Member, CEO, and entrepreneur with direct leadership experience across the R&D-manufacturing-commercial continuum in therapeutics, diagnostics, medical devices, and over-the-counter (OTC) consumer healthcare products. As CEO, he has led multi-billion-dollar, mid-sized, and start-up life science companies/divisions in the USA, Canada, and the United Kingdom/Ireland. He is currently Chairman & CEO of Cytosolix, Inc., an early stage, venture-backed oncology life science company spun out of Yale University, a board member of Ascendia Pharmaceuticals, an Entrepreneur-in-Residence at Yale University, an Executive-in-Residence & Senior Industry Advisor at Columbia University, and a member of the New York University Langone Health Investment Committee. Previously, Colin was CEO of iSci Management, board member & CEO of Bioblast Pharma Ltd (NASDAQ), Executive Chairman of Ivenix, Inc., and a co-founder, board member, and CEO of Optherion, Inc. Earlier, Colin was President & CEO of Bayer Pharmaceuticals Corporation USA, Region Head of the North American Pharmaceuticals Group of Bayer AG, and a member of Bayer AG’s Global Pharmaceutical Operating Committee. Colin has a B.Sc. in Zoology and Microbiology from the University of Toronto, an M.B.A. from the Ivy School of Business at Western University in Canada, and his Canadian Securities Certificate. He is a citizen of Canada, the United States of America, and the United Kingdom.

John received a B.A. from the University of California, Berkeley, and a Ph.D. in Molecular Cellular & Developmental Biology from the University of Colorado, Boulder. He invented the core technology of Cytosolix during his postdoctoral research in the Engelman Lab at Yale University, where his work establishing drug-linker chemistries for tumor-targeting peptides is now used in clinical-stage agents. John is lead inventor on all Cytosolix’s platform patents and led development of the technology as an Associate Research Scientist at Yale, securing over $2M in pilot funding, and managing a large collaborative research effort. In parallel to his research efforts, John has participated in a variety of biotech entrepreneurial programs including at the Yale Entrepreneurial Institute and CTNext's Accelerator in Biosciences for Connecticut (ABCT). John is the recipient of a PITCH grant from Connecticut Innovations, and three Blavatnik Awards at Yale supporting the translational development of the platform.